 This study found that succukinumab, a biological drug used to treat hydradinitis suprativa, was effective in treating moderate to severe cases of the condition. It also showed that female gender, lower body mass index, and fewer medical treatments and surgeries before starting on succukinumab were associated with better outcomes. This article was authored by Pablo Fernández-Crehuit, Sofia Hazelgruba, Alicia Pedro Gomez, and others.